Drug Approval | October 19, 2021
Dr Reddy’s Labs announces U.S. FDA approval for Lenalidomide capsules
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
_256_384.jpg)
The platform will be a curated marketplace for sustainable-driven products by small-medium entrepreneurs and will encourage an autonomous marketplace
The revised deal involves a cash consideration only as against the earlier proposal of cash and equity
The consortium envisages carrying out surveillance of important bacterial, viral and parasitic infections of zoonotic as well as transboundary pathogens
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
This is a virtual event and the theme is `Transforming Healthcare beyond Covid’
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
This opens up a huge market for the company’s Magnezis implants in India
Subscribe To Our Newsletter & Stay Updated
